Professor Jukka Westermarck received Orion Research Foundation’s special grant of EUR 100,000
Professor Jukka Westermarck has been carrying out research into the biology of cancer for almost 30 years. His research group has endeavoured to identify signalling mechanisms in cancer cells that promote malignancy in cancer. The group’s most significant achievement has been identification of the CIP2A oncoprotein. This has provided new outlooks regarding the future opportunities of cancer treatment.
Westermarck, who carries out internationally significant research and actively advocates for better conditions for doing research, received Orion Research Foundation’s special grant of EUR 100,000 on 27 October.
“I am really pleased about this. In addition to research, the award considers scientific policy lobbying, which I have always felt to be very important.”
For a long time, Westermarck has been furthering the cause of funding for biomedicine and clinical medicine research. “I have also wanted to provoke general discussion on the role of science in Finland. It can certainly be measured by the amount of funding, but universities also need space to do things more freely.” [continue reading]
Recent Posts
- Early-career researchers invited to BioCity Pre-Symposium on 26 August. Registration is now open!Doctoral researchers at BioCity Turku are organising a pre-symposium on 26 August 2026, offering early-career Read moreApril 30, 2026
- 35th BioCity Symposium is arranged 27–28 August 2026. Registration is now open!This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026